KR102264006B1 - Composition for inhibiting production of melanin and promoting decomposition of melanin - Google Patents

Abstract

The present invention relates to a composition comprising an extract of Eriobotrya japonica leaves and spearmint. The composition according to the present invention has excellent effects of inhibiting melanin production and promoting decomposition, and can be applied to various fields such as cosmetics, food, and pharmaceuticals.

Description

Composition for inhibiting melanin production and promoting decomposition {COMPOSITION FOR INHIBITING PRODUCTION OF MELANIN AND PROMOTING DECOMPOSITION OF MELANIN}

The present invention relates to a composition comprising an extract of loquat leaves and spearmint. The composition according to the present invention has excellent effects of inhibiting melanin production and promoting decomposition, and can be applied to various fields such as cosmetics, food, and pharmaceuticals.

For promoting the breakdown of melanin

Human skin undergoes various physical and chemical changes during the aging process, and aging can be largely divided into intrinsic aging and photo-aging depending on the cause. Free radicals are activated depending on UV rays, stress, disease state, environmental factors, wounds, aging, etc., which can cause skin aging, and if this condition worsens, it destroys the antioxidant defense network that exists in the body and damages cells and tissues. It can lead to That is, as lipids, proteins, polysaccharides, nucleic acids, etc., which are major constituents of the skin, are oxidized and skin cells and tissues are destroyed, skin aging becomes more severe. In particular, the oxidation of proteins cuts collagen, hyaluronic acid, elastin, proteoglycan, fibronectin, etc., which are the connective tissues of the skin, causing a severe hyperinflammatory reaction and lowering skin elasticity. cause functional decline.

The aging process of the skin is accompanied by changes in the skin due to pigmentation. At this time, pigments that affect skin color include melanin, melasoid, carotene, hemoglobin, and the like. Among them, melanin is the most important, and the factors that affect the biosynthesis of melanin are ultraviolet rays and the degree of hormone secretion in the body. Melanin has no specific maximum absorption wavelength and absorbs light in all areas. In addition, melanin has an excellent function of removing reactive oxygen species, but sometimes melanin itself generates active oxygen, and reduces or oxidizes other substances by catechol or quinone in the melanin structure, and melanin itself is a free radical It also indicates character. Therefore, melanin plays a role in protecting skin cells from UV damage by absorbing UV, but when melanogenesis is excessive, melanin is excessively deposited on the skin, resulting in the appearance of spots, freckles, and melanoma. Because it causes skin pigmentation disease, it is required to maintain the balance of the amount of melanin at an appropriate level.

Therefore, in order to find a substance that can effectively control melanin, research is being actively conducted in various fields such as pharmaceuticals, cosmetics, and food. However, the results studied so far are mostly about substances that inhibit the production of melanin in the biosynthetic process of melanin, that is, show the prophylactic effect. On the other hand, there is a large unmet demand for a material capable of efficiently decomposing previously generated melanin, that is, a material capable of exhibiting therapeutic efficacy as well as preventive efficacy.

Autophagy generally refers to the process of decomposing damaged or unnecessary components or organelles in cells and reproducing them as energy sources. Proteins or cellular components that are no longer needed in the cell are surrounded by an autophagosome membrane as autophagy activity is increased to form autophagosomes. After the lysosome is fused here, a hydrolase in the lysosome breaks down and releases the substance in the endoplasmic reticulum. These released products are used to create new organelles.

Recently, as interest in autophagy increases, various studies are being conducted, and it is also reported that melanin, which plays an important role in the skin aging process, can be decomposed by autophagy. Accordingly, there is a very high need for a material that can effectively decompose melanin previously generated in melanocytes by autophagy.

In order to solve the problems of the prior art, the present inventors have studied for a long period of time, experimentally demonstrating that extracts of loquat leaves and spearmint not only inhibit melanin production but also promote melanin degradation. came to

According to one embodiment of the present invention, there is provided a composition for inhibiting melanin production and promoting melanin degradation, comprising an extract of loquat leaves and spearmint.

The loquat belongs to the Rosaceae family, and its leaves are called loquat leaves and its seeds are called loquats. The scientific name is Eriobotrya Japonica, and it is distributed in Korea, Japan, and China. Loquat leaves are registered with INCI (International Nomenclature Cosmetic Ingredient) and CFDA (Chinese Food and Drug Administration).

The spearmint belongs to the mint genus, and the scientific name is Mentha Viridis, Mentha spicata or Spearmint, and is distributed in Europe and Asia. Spearmint is registered with INCI (International Nomenclature Cosmetic Ingredient) and CFDA (Chinese Food and Drug Administration).

In the composition according to the present invention, loquat and spearmint may be used without limitation, such as cultivated, collected, or commercially available ones.

As used herein, the term “raw material” refers to a raw material before extraction as a raw material.

As used herein, the term "extract" refers to a result obtained by extracting a crude drug with an appropriate extraction solvent, which includes an extract obtained by extraction treatment, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, and adjustments thereof It is construed to include an offering or a purified product, or a fraction. Preferably, the active ingredient of the composition according to the present invention can be obtained by extracting a complex of loquat leaves and spearmint, for example, by extracting a combination in a dried form of loquat leaves and spearmint aerial parts.

The extract according to the present invention can be prepared using a general extraction method known in the art, for example, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction, high-temperature pressure extraction, etc. can be used. have.

The extraction solvent used for preparing the extract according to the present invention includes water; lower alcohols having 1 to 4 carbon atoms, such as methanol, ethanol, propyl alcohol, and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; hydrocarbon solvents such as methyl acetate, ethyl acetate, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof may be included, but is not limited thereto. Preferably, alcohol may be used as the extraction solvent, and particularly preferably, 70% ethanol may be used. The extraction solvent may be used in an amount of about 4 to 50 times the dry weight of the complex.

Preferably, in the method for preparing the composition of the present invention, the complex extract can be obtained by a) reflux extraction of loquat leaves and spearmint with 70% ethanol. For example, in step a), loquat leaves and spearmint may be extracted using 70% ethanol at a temperature of 4°C to 80°C for 1 to 24 hours.

Optionally, prior to step a), washing and drying raw materials of loquat leaves and spearmint may be included.

Optionally, b) filtering may be included. For example, in step b), it may be filtered with a 1.0 ~ 0.2μm filter.

Optionally, it may include the step of c) concentration under reduced pressure.

Optionally, it may comprise the step of d) fractionating the filtrate or the concentrate.

Optionally, e) obtaining a fraction via open column chromatography.

The complex extract obtained in steps a), b), c), d) or e) may be included as an active ingredient of the composition according to the present invention.

According to another embodiment of the present invention, there is provided a cosmetic composition comprising an extract of loquat leaves and spearmint as active ingredients.

The content of the extract included as an active ingredient in the cosmetic composition according to the present invention may be suitably determined in consideration of various factors such as purpose of use, period of use, type of formulation, route of administration, skin condition of the subject, and degree of melanin accumulation in the subject. For example, the content of the complex extract may be 0.0001 to 10% by weight, such as 0.001 to 5% by weight, based on the total weight of the cosmetic composition.

The loquat leaves and spearmint may be each in an amount of 2 to 98% by weight based on the total weight of the complex extract. Preferably, the complex extract of loquat leaves and spearmint may include 50.0 to 98.0 parts by weight of loquat leaves and 2.0 to 50.0 parts by weight of spearmint.

The cosmetic composition according to the present invention may be prepared in the form of a general emulsified formulation and a solubilized formulation using a conventionally known manufacturing method. At this time, the cosmetic composition of the present invention includes patches, ointments, gels for skin adhesion, creams, packs, lotions, essences, sprays, masks, foundations, makeup bases, detergents, water (W) type, Oil (O) type, silicone (S) type, oil-in-water (O/W) type, water-in-oil (W/O) type, water-in-silicone (W/S) type, silicone in water (S/W) type, solid, It can be prepared in various formulations such as liquid, and a method for preparing a cosmetic commonly used can be applied.

The cosmetic composition according to the present invention may further include additional ingredients in addition to the extract to enhance efficacy. For example, the additional ingredients are not limited as long as they do not counteract or reduce the efficacy of the extract. Optionally, it may further include adjuvants, carriers, etc. commonly used in the cosmetic field. Optionally, ingredients typically used to add or enhance cosmetic functions may also be added. For example, stabilizers, emulsifiers, thickeners, humectants, liquid crystal film strengthening agents, pH regulators, antibacterial agents, water-soluble polymers, film agents, sequestering agents, amino acids, organic amines, polymer emulsions, pH regulators, skin nutrients, antioxidants, one or more aqueous additives selected from antioxidants, preservatives, fragrances, and the like; and at least one oily additive selected from oils and fats, waxes, hydrocarbon oil, higher fatty acid oil, higher alcohol, synthetic ester oil, and silicone oil.

According to another embodiment of the present invention, there is provided a food composition comprising an extract of loquat leaves and spearmint as active ingredients.

The food may be a health functional food. The term "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients useful for the human body. Herein, the term "functionality" refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological actions with respect to the structure and function of the human body.

The food composition according to the present invention can be prepared by a method commonly used in the art, and during the preparation, it can be prepared by adding raw materials and components commonly added in the art. In addition, since the food composition according to the present invention contains a natural plant extract as an active ingredient, there is no side effect or resistance that may generally occur during long-term administration. Therefore, the food composition according to the present invention can be used alone as well as with the cosmetic composition, pharmaceutical composition, and/or other composition or other therapy according to the present invention for the purpose of maximizing the effect of inhibiting melanogenesis and decomposing melanin. It is also possible to use them simultaneously or sequentially.

The content of the extract included as an active ingredient in the food composition according to the present invention may be suitably determined according to the purpose of use, the period of use, the skin condition of the subject or the degree of melanin accumulation, the desired effect generation time, and the like. For example, the content of the complex extract may be 0.0001 to 100% by weight, such as 0.001 to 10% by weight, based on the total weight of the food composition.

The loquat leaves and spearmint may be each in an amount of 2 to 98% by weight based on the total weight of the complex extract. Preferably, the complex extract of loquat leaves and spearmint may include 50.0 to 98.0 parts by weight of loquat leaves and 2.0 to 50.0 parts by weight of spearmint.

The food composition according to the present invention may further include an additional ingredient in addition to the active ingredient to enhance efficacy. For example, as long as the additional component does not offset or reduce the efficacy of the complex extract, a component or agent exhibiting an effect of inhibiting the decomposition of pre-generated melanin, a component exhibiting an effect of blocking or inhibiting the production of melanin, or formulations and the like.

The food composition may be in the form of pills, tablets, granules, powders, capsules, liquids, and the like. In addition, the type of the food is not particularly limited. Examples of foods to which the food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks , alcoholic beverages, vitamin complexes, and the like, and includes all foods in a conventional sense.

The food composition of the present invention may contain various flavoring agents or natural carbohydrates used in conventional foods as additional ingredients. The natural carbohydrate may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.

According to another embodiment of the present invention, there is provided a pharmaceutical composition comprising an extract of loquat leaves and spearmint as active ingredients.

The pharmaceutical composition may be provided for the treatment or prevention of skin pigmentation disease. Melanin plays a role in protecting skin cells from UV damage by absorbing UV rays, so it is an essential component for humans. As used herein, the term “skin pigmentation disease” refers to a disease caused by being deposited on the skin as a skin pigment such as melanin is produced in excess of an appropriate level. For example, skin cancer, blemishes, melasma, freckles, age spots, melanoma, solar tigines, senile pigmentation spots, macules, hyperpigmentation of genetic factors, hyperpigmentation of metabolic or drug-related origin, etc. may be included, but is not limited thereto.

As used herein, the term “treatment” refers to any action in which the symptoms of skin pigmentation disease are improved or cured by administration of the composition according to the present invention. In addition, the term "prevention" refers to any action of suppressing or delaying the symptoms of skin pigmentation disease by administering the composition according to the present invention.

The content of the active ingredient contained in the pharmaceutical composition according to the present invention may be suitably determined according to the symptoms of the disease, the degree of progression of the symptoms, the patient's condition, age, sex, and the like. For example, the cheonnamseong extract of the present invention may be included in an amount of about 0.0001 to 100% by weight based on the total weight of the pharmaceutical composition.

The pharmaceutical composition according to the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceuticals. Carriers, excipients and diluents that may be contained in the composition include, for example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose. , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.

The pharmaceutical composition according to the present invention may be an oral dosage form. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. in the extract. It can be prepared by mixing. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . In addition, the pharmaceutical composition according to the present invention may be formulated into a dosage form suitable for topical administration using techniques well known to those skilled in the art, and the dosage form may include external preparations, effervescent tablets, suppositories, and the like. In one embodiment, the pharmaceutical composition of the present invention may be formulated for external use by mixing the extract with a well-known and commonly used base in the art. The external preparation may be an emulsion, gel, ointment, cream, patch, linen, powder, aerosol, spray, lotion, serum, paste, foam, dropper, suspension or tincture.

The pharmaceutical composition according to the present invention is administered to a subject in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level includes the subject type and severity, age, sex, drug activity, sensitivity to drugs, administration time, administration route and excretion rate, duration of treatment, factors including concurrent drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. It may also be administered single or multiple. The pharmaceutical composition of the present invention may be administered in an amount of 0.1 to 100 mg/kg once to several times a day, depending on the age, sex, weight, administration route, degree of disease, etc. of the patient, but is not limited to the above range.

The present invention will be described in more detail based on the following examples and drawings attached to the present specification, but it is not intended to limit the scope of the present invention. In addition, those of ordinary skill in the art will be able to make various changes and modifications to the present invention within the scope that does not impair the spirit of the present invention.

The composition comprising the complex extract according to the present invention can significantly enhance autophagy activity in the skin, and thus it is possible to promote the decomposition of pre-generated melanin. In addition, it is possible to significantly inhibit the overproduction of melanin.

In particular, since the decomposition rate of the pre-generated melanin is fast, it is possible to quickly show the improvement or therapeutic effect of a condition or disease caused by the excessively generated melanin. Therefore, it is useful for a subject who wants to obtain a cosmetic effect at an early stage, or a patient suffering from a disease caused by melanin hyperdeposition.

Moreover, the complex extract included as an active ingredient in the composition according to the present invention has been proven to decompose melanin without toxicity in a test to be described later, ensuring safety for the human body.

As such the composition of the present invention can be applied to various fields requiring melanin decomposition, it may be provided in the form of cosmetics, or alternatively, it may be provided in the form of functional food or food supplements, and may be provided in the form of pharmaceuticals. may be

1 is a graph showing cell viability when treated with a single extract of loquat leaves and a complex extract of the present invention for B16F1 melanoma.
Figure 2 is a graph showing the melanin production inhibitory activity when treated with a single extract of loquat leaves and the complex extract of the present invention for B16F1 melanoma.
3 is a graph showing the melanin production inhibitory activity when treated with ursolic acid obtained through the purification process of the complex extract of the present invention for B16F1 melanoma.
4 is a fluorescence staining microscope photograph showing autophagy factor activity when treated with ursolic acid obtained through the purification process of the complex extract of the present invention for B16F1/GFP-LC3 melanoma, and green fluorescence intensity. It is a graph showing quantification.

Hereinafter, a specific example will be described to help the understanding of the present invention. However, the following examples should not be construed as limiting the present invention, and ordinary changes of those skilled in the art are possible within the scope of the present invention.

Example 1

Loquat leaves and spearmint were purchased commercially and used in this experiment. 5 kg (total weight) of a raw material containing loquat leaves and spearmint was prepared in the following composition ratio: loquat leaves 4.0 kg (80.0 weight %), spearmint 1.0 kg (20.0 weight %). 10 times the volume of 70% ethanol was added to the raw material, extracted at 80° C. for 3 hours, cooled and filtered, and concentrated to dryness. The product thus obtained was used in Test Examples to be described later.

Comparative Example 1

10 times the volume of 70% ethanol was added to 5 kg (total weight) of loquat leaves prepared as in Example 1, extracted at 80° C. for 3 hours, cooled, filtered, and concentrated to dryness. The product thus obtained was used in Test Examples to be described later.

Test Example 1: Cytotoxicity to B16F1 melanoma

In order to confirm the cytotoxicity of the complex extract of Example 1 and the loquat leaf extract of Comparative Example 1, cell viability was measured.

Specifically, B16F1 melanoma cells were seeded in a 96-well plate at 6x10 ³ cells/well. As a medium for culturing cells, DMEM medium supplemented with 10% FBS and 1% Penicillin-Streptomycin (Invitrogen, Carlsbad, CA, USA) was used. Then, it was cultured for one day in a 5% CO _{2 incubator at 37°C.} After removing all of the medium supernatant, a culture medium treated with 1 μM of α-MSH and a sample concentration of 1% was added, and cultured at 37° C. in 5% CO _{2 in an} incubator for 24 hours.

20 μl of MTS (Promega, G3581, Cell titer 96 Aqueous One Solution) was added and _{reacted for 2 hours in an incubator at 5% CO 2} at 37° C., using Envision (Perkin-Elmer, A485-MTS assay 96-well) to measure the number of cells.

As can be seen in Fig. 1 showing the experimental results, when the extract according to the present invention was treated with B16F1 melanoma cells at an amount of 0.5 to 1.0%, there was no significant difference in cell viability compared to the negative control group using DMSO, It showed a cell viability of more than 90%.

Therefore, the extract according to the present invention does not affect the viability of B16F1 melanoma cells even when used at a high concentration. This means that the extract according to the present invention does not exhibit unexpected side effects such as toxicity to normal cells.

Test Example 2. Inhibition of melanin production in B16F1 melanoma cells

B16F1 melanoma cells were seeded in a 6-well plate at a volume of 6x10 ⁴ cells/well. As a medium for culturing cells, DMEM medium supplemented with 10% FBS and 1% Penicillin-Streptomycin (Invitrogen, Carlsbad, CA, USA) was used. Then, it was cultured for one day in a 5% CO _{2 incubator at 37°C.} After removing all of the medium supernatant, a culture medium treated with 1 μM of α-MSH was added, and cultured at 37° C. in 5% CO _{2 in an} incubator for 48 hours. Here, α-MSH refers to α-melanocyte stimulating hormone, and is a substance that induces melanin production. Thereafter, a culture medium was added to the sample at a concentration of 1%, and incubated for 24 hours at _{37° C. in 5% CO 2 in an incubator.} After incubation, cells were recovered through Trypsinisation, lysed by treatment at 100° C. for 30 minutes in Solubilisation buffer, and absorbance was measured at 405 nm.

As can be seen in FIG. 2 showing the experimental results, the complex extract according to the present invention inhibits melanin biosynthesis at a significantly higher level than the single extract of loquat leaves. Although the loquat leaf single extract also has an excellent melanogenesis inhibitory effect, the loquat leaf and spearmint complex extract has a significantly better melanogenesis inhibitory effect, indicating an enhanced whitening effect according to the melanogenesis inhibition.

Test Example 3. Identification of ursolic acid in the complex extract

10 times the volume of 70% ethanol was added to the raw material prepared as in Example 1, extracted at 80° C. for 3 hours, cooled and filtered, and concentrated to dryness to obtain 1 kg.

The resulting extract was suspended in water and fractionated successively in the order of hexane, ethyl acetate, and n-butanol. The ethyl acetate fractional layer of the complex extract was concentrated using a reduced pressure concentrator. The concentrate was injected into column chromatography filled with silica gel (230-400 mesh, Merck), chloroform 3L was added, and chloroform:methanol 49:1, 19:1, 9:1, 4:1, 1: It was sequentially eluted with a developing solvent in a ratio of 1, and a first fraction was obtained among the eluted fractions.

The first fraction was subjected to column chromatography in which dichloromethane:methanol (1:1) was filled with reverse phase silica gel (ODS-A, RP-18) as a mobile phase. Column chromatography filled with Sephadex LH-20 was performed to obtain 23 mg of a white solid. It was identified that the white solid thus obtained was ursolic acid having the following chemical structure, and the purity of ursolic acid was confirmed to be 89.50% by HPLC-DAD:

.

.

Test Example 4. Inhibition of melanin production in B16F1 melanoma

In this test example, it was intended to evaluate the effect of ursolic acid contained in the complex extract of the present invention on melanin production.

B16F1 melanoma cells ^{were aliquoted in a 6-well plate so as to become 6x10 4} cells/well, and DMEM medium containing 1 μM of α-MSH was supplied and _{pre-cultured at 37° C., 5% CO 2 in an} incubator for 24 hours. After 24 hours, the ursolic acid obtained in Test Example 3 was treated with two concentrations (5 μM, 10 μM) and cultured for 48 hours.

Then, the culture medium was removed, washed with PBS, and then treated with trypsin to collect cells in a microtube. The recovered cells were lysed with 1N NaOH containing 10% DMSO, and then intracellular melanin was dissolved in a thermostat at 100° C. for 30 minutes. By measuring the absorbance at 405 nm using an ELISA reader, the intracellular melanin content was calculated according to the following formula.

Melanin production rate (%) = (response absorbance of control group - absorbance of cell culture medium response of extract/response absorbance of control group) x 100

As can be seen in FIG. 3 showing the results, it was confirmed that ursolic acid obtained from the complex extract of the present invention exhibits a concentration-dependent effect of inhibiting melanin production.

Test Example 5. Melanosome degradation by melanophage activation in B16F1 melanoma

It has been reported that ursolic acid induces autophagy in cancer cells (Luo J, Hu YL, Wang H. Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NF-κB signaling pathways in vitro. Exp Ther Med. 2017;14:3623-3631).

In this test example, it was attempted to determine whether ursolic acid according to the present invention induces autophagy in B16F1 melanoma cells.

GFP-LC3 cell line (B16F1/GFP-LC3) was obtained from B16F1 melanoma cell line by tagging GFP fluorescent protein to LC3 protein used as an autophagy activity marker. Then, the B16F1/GFP-LC3 cell line was treated with ursolic acid obtained in Test Example 3 at two concentrations (5 μM, 10 μM).

During the mechanism of autophagy activation, LC3I protein is converted to LC3II protein and is involved in autophagy activity. That is, as the LC3I protein is converted to the LC3II protein, an autophagosome is formed to generate a spherical vesicle with fluorescence, thereby amplifying the fluorescence value. The fluorescence image and intensity of a cell surrounded by an autophagosome membrane are shown in FIG. 4 . The higher the fluorescence intensity value, the more the previously generated melanin was decomposed into individual amino acids by the autophagosome formed in the autophagy process.

As shown in Figure 4, it was demonstrated that ursolic acid increases the autophagy activity of the melanocyte model.

Claims (7)

A composition for promoting melanin decomposition comprising a complex extract of loquat leaves and spearmint containing ursolic acid as an active ingredient,
The composition is to decompose the previously generated melanin by autophagy, a composition for promoting melanin decomposition. delete According to claim 1,
The complex extract is characterized in that obtained using a solvent selected from water, alcohol, or a mixture thereof, a composition for promoting melanin decomposition. delete According to claim 1,
The composition is a cosmetic composition, characterized in that the composition for promoting melanin decomposition. According to claim 1,
The composition is a food composition, characterized in that the composition for promoting melanin decomposition. According to claim 1,
The composition is selected from the group consisting of skin cancer, blemishes, melasma, freckles, age spots, melanoma, solar melanosis, senile pigmentation, spots, hyperpigmentation of genetic factors, or hyperpigmentation of metabolic or drug-related origin. A composition for promoting melanin degradation, characterized in that it is a pharmaceutical composition for the treatment or prevention of diseases.

Images